1 / 1

TSEI - Associated Malignant Melanoma in Mycosis Fungoides

TSEI - Associated Malignant Melanoma in Mycosis Fungoides. Lutsyk M, Kuten A, Cohen Y, Barchana , M. Division of Oncology, Radiotherapy Unit, Rambam Health Care Campus, Haifa, Israel. Introduction. Results.

lupita
Download Presentation

TSEI - Associated Malignant Melanoma in Mycosis Fungoides

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TSEI - Associated Malignant Melanoma in Mycosis Fungoides Lutsyk M, Kuten A,Cohen Y, Barchana, M. Division of Oncology, Radiotherapy Unit, Rambam Health Care Campus, Haifa, Israel Introduction Results According to the Annual Report of the Israel National Cancer Registry for 2007, the Age Standardized Rate of Malignant Melanoma (MM)for JewishMales is 13.5 per 100.000 and for Jewish Females -10.3 per 100,000. Increased risk of secondary cancers in patients with Primary Cutaneous T cell Lymphoma (CTCL) has already been reported. The following is a report of 7 cases of MM in cohort of 196 patients with Mycosis Fungoides (MF) treated at Rambam Health Care Campus. Seven cases of MM in MF patients were identified. Five patientsweretreated with Total Skin Electron Irradiation (TSEI), one patient was treated with involved field skin electron irradiation (SubTSEI), and one had no radiotherapy. Two patients were treated with PUVA or Mustard Nitrogen (MN) topically and one received total body photon irradiation in addition to TSEI. Most of the patients had early stage (IA-IB) MF. Fig. 1 ASR of Skin Melanoma in Israel, 1980 - 2007 Table 1. Demographic and treatment data of the 7 MF pts with MM Objective Conclusion To present the Rambam Health Care Campus experience of patients with MF and malignant melanoma. The prevalence  of second primary MM in MF patients was much higher than expected – 3,6%. The mechanism of the phenomenon may be related to a host immunomodulation that results in CTCL pathogenesis and/or in sun exposure influence in combination with electron beam radiotherapy. Methods The database of the Rambam Radiotherapy Unit comprised the management of 250 MF patients treated in the years 1960-2010. Data of 196 patients were available for this analysis. The Israel NationalCancer Registry was queriedfor second primary tumors in these patients. Contact information: Dr.Lutsyk Myroslav, MD, Division of Oncology, Rambam HealthCareCampus, Haifa 31096, Israel. e-mail: myroslavl@gmail.com

More Related